Literature DB >> 2838755

HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor.

K Leung1, G J Nabel.   

Abstract

Like other viruses that infect primate cells, the human T lymphotropic virus-I (HTLV-I) stimulates production of some host cell proteins. In particular, HTLV-I infected T cells synthesize interleukin-2 receptor alpha (IL-2R alpha) chain, which is probably induced through the mediation of the tat-I gene product of the virus. Activated T cells contain a trascription factor called NF-kappa B, which stimulates the expression of human immunodeficiency virus-1 (HIV-1) by binding to an 11-base-pair enhancer sequence called kappa B. We have now found evidence that a similar transcription factor is involved in the induction of IL-2R alpha expression by tat-I. We have identified a sequence upstream of IL-2R alpha which is the same as the kappa B site at 9 of 11 base pairs, competes for binding to the kappa B sequence, and serves as a tat-I responsive element when multiple copies are inserted upstream of a heterologous promoter. The tat-I product also induces kappa B and the IL-2R alpha kappa B binding activity in transfected Jurkat T lymphoid leukaemia cells. Both HTLV-I and HIV-1 thus interact with NF-kappa B-like transcription factors which might normally regulate expression of a growth factor receptor gene.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838755     DOI: 10.1038/333776a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  240 in total

1.  Immortalization of T lymphocytes by human T-cell leukemia virus type 1 is independent of the tax-CBP/p300 interaction.

Authors:  M D Robek; L Ratner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features.

Authors:  K Eguchi; N Matsuoka; H Ida; M Nakashima; M Sakai; S Sakito; A Kawakami; K Terada; H Shimada; Y Kawabe
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1.

Authors:  D M Markovitz; M C Hannibal; M J Smith; R Cossman; G J Nabel
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 7.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Identification of multiple cis-elements and trans-acting factors involved in the induced expression of human IL-2 gene.

Authors:  H Shibuya; T Taniguchi
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

9.  Tax induces nuclear translocation of NF-kappa B through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of I kappa B alpha/MAD3.

Authors:  E Muñoz; G Courtois; P Veschambre; P Jalinot; A Israël
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Infection with the intracellular protozoan parasite Theileria parva induces constitutively high levels of NF-kappa B in bovine T lymphocytes.

Authors:  V Ivanov; B Stein; I Baumann; D A Dobbelaere; P Herrlich; R O Williams
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.